The synergy of myopathic valvular disease
The synergy of myopathic valvular disease
About this item
Full title
Author / Creator
Publisher
England: BMJ Publishing Group Ltd and British Cardiovascular Society
Journal title
Language
English
Formats
Publication information
Publisher
England: BMJ Publishing Group Ltd and British Cardiovascular Society
Subjects
More information
Scope and Contents
Contents
With recent advancements in the treatment of heart failure with reduced ejection fraction (HFrEF) including the addition of angiotensin receptor–neprilysin inhibitor, sodium–glucose cotransporter 2 inhibitors (SGLT2i) and transcatheter edge-to-edge mitral valve repair (TEER), the treatment of patients with cardiomyopathy and secondary mitral regurg...
Alternative Titles
Full title
The synergy of myopathic valvular disease
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2674757038
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2674757038
Other Identifiers
ISSN
1355-6037
E-ISSN
1468-201X
DOI
10.1136/heartjnl-2022-321214
